| Document |
Document Title |
|
WO/2006/023457A1 |
This invention provides compounds of formula I wherein R1, R2, R3, R4, R5, R6, R7, R8a, R8b, W, a and b are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The compounds of this ...
|
|
WO/2006/018326A1 |
The invention relates to novel biaromatic compounds that correspond to the general formula (I) and also to the method for preparing them, and to their use in pharmaceutical compositions for use in human or veterinary medicine (in dermato...
|
|
WO/2006/015852A1 |
Compounds of formula (I) in free or salt form, wherein T, X, R1, R2, Ra, R3, R4, R5 and U have the meanings as indicated in the specification, are useful for treating a condition mediated by CCR-3, particularly an inflammatory or allergi...
|
|
WO2004101752A3 |
Novel acyl urea, carbamate, thiocarbamate and related compounds are provided which are effective in inhibiting the cytokine-mediated inflammatory response in cultured cells, in ameliorating bone destruction in an animal model of arthriti...
|
|
WO2005058798A3 |
Compounds of formulas 1 through 17 provided in the specification specifically or selectively inhibit either the cytochrome P450RAI-1 enzyme or the cytochrome P450RAI-2 enzyme.
|
|
WO/2006/017216A1 |
This invention relates to hydroxamic acid derivatives having a urea linkage, that are inhibitors of histone deacetylase (HDAC), and are useful in the prevention and/or treatment of cellular proliferative diseases, for example cancer, aut...
|
|
WO/2006/010362A1 |
The invention relates to 1-amino adamantane derivatives and 3-amino adamantane-1-carboxylic acid derivatives, wherein the 5th and/or 7th position of the adamantane base frame can be substituted in any particular manner. The invention als...
|
|
WO/2006/011420A1 |
Disclosed is a compound represented by the general formula (1) below. (1) [In the formula, R represents a hydrogen atom or a lower alkyl group; X represents a sulfur atom or an oxygen atom; Y represents a chain, branched or cyclic alkyl ...
|
|
WO2005113511A9 |
The present invention provides novel pyridyl or phenyl ureas and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods fo...
|
|
WO/2006/006725A1 |
The present invention provides a reversible thermosensitive recording medium including a support and a thermosensitive recording layer thereon, in which the thermosensitive recording layer comprises an electron-donating coloring compound...
|
|
WO/2006/003923A1 |
Disclosed is an excellent LXR modulator. Specifically disclosed are compounds represented by the following general formula (I). (In the formula, R1 represents -COR9 (wherein R9 represents an alkyl, an optionally substituted alkoxy or an ...
|
|
WO/2006/002474A1 |
Benzoyl urea derivatives that are alpha helical peptide mimetics that mimic BH3-only proteins, compositions containing them, their conjugation to cell-targeting moieties, and their use in the regulation of cell death are disclosed. The b...
|
|
WO/2005/123666A1 |
The invention relates to compounds of formula (I), wherein R e R1, R2, X and n are as defined in the description, and their use for the preparation of pharmaceutical compositions for the treatment of inflammatory states.
|
|
WO2004098512A3 |
The present application describes modulators of MCP 1 of formula (I) or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.
|
|
WO/2005/122379A2 |
The present invention provides a 4ß1 integrin ligands that display high binding affinity, specificity, and stability. The ligands comprise a peptide having n independently selected amino acids, wherein at least one amino acid is an unna...
|
|
WO2005061443A3 |
The invention relates to benzoyl-substituted phenylalanine amides of formula (I), wherein the variables R<1> to R<15> have the meanings indicated in the description, the agriculturally useful salts thereof, methods and intermediate produ...
|
|
WO/2005/114331A1 |
A resist composition which comprises one or more resist compounds (A) satisfying all of the requirements of (a) having, in the molecule thereof, at least one crosslinking group undergoing a crosslinking reaction directly or indirectly by...
|
|
WO/2005/113511A1 |
The present invention provides novel pyridyl or phenyl ureas and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods fo...
|
|
WO2005082862A3 |
The present invention relates to benzimidazolyl derivatives of formula (I), with the definitions of R<8>, p, Ar<1>, E, D, R<9>, q and R<10> according to claim 1, the use of the compounds of formula (I) as inhibitors of one or more kinase...
|
|
WO/2005/107762A2 |
Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.
|
|
WO/2005/108352A1 |
The invention relates to novel biaromatic compounds which correspond to the following general formula (I) and to their method of preparation and to their use in pharmaceutical compositions intended for use in human or veterinary medicine...
|
|
WO/2005/108370A1 |
It is intended to provide benzene compounds represented by the following formulae and analogs thereof which exert an ACC activity inhibitory effect and are efficacious in treating hyperlipemia, fatty liver, impaired glucose tolerance, di...
|
|
WO/2005/105737A1 |
The present invention relates to novel processes for the preparation of substituted tetralin and substituted indane derivatives. The present invention is further directed to novel processes for the preparation of intermediates in the pre...
|
|
WO/2005/097737A1 |
The invention relates to a method for producing polyisocyanate prepolymers comprising allophanate structural units, using zinc compounds as catalysts and to the use of said prepolymers for producing polyurethanes and polycarbamides.
|
|
WO/2005/097773A1 |
The present invention is related to carboxylic acids of Formula (I) and use thereof for the treatment and/or prevention of obesity and/or metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and...
|
|
WO2005058798A8 |
Compounds of formulas 1 through 17 provided in the specification specifically or selectively inhibit either the cytochrome P450RAI-1 enzyme or the cytochrome P450RAI-2 enzyme.
|
|
WO/2005/095333A1 |
The present invention relates to polymorphic forms of (1-&lcub 3-[3-(4-cyano-3-methoxy-phenyl)ureido]-phenyl&rcub -ethyl)-carbamic acid-2-cyano-1-ethyl-ethyl ester, processes therein, pharmaceutical compositions thereof, and uses therewith.
|
|
WO/2005/092843A1 |
This invention relates to novel urea derivatives, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases ...
|
|
WO/2005/092841A1 |
The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invent...
|
|
WO/2005/090288A1 |
The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invent...
|
|
WO2005070871A3 |
The application relates to novel amino alcohols of general formula (I) where R, R1, R2, R3, R4, R5, X1 and X2 each have the definitions illustrated in detail in the description, to a process for their preparation and to the use of these ...
|
|
WO/2005/087215A1 |
The invention relates to acetyl 2-hydroxy-1,3-diaminospirocyclohexanes and derivatives thereof that are useful in treating at least one disease, disorder, and condition associated with amyloidosis. Amyloidosis refers to a collection of d...
|
|
WO2005056520A8 |
This invention relates to a group of novel somatostatin receptor subtype 1 (SSTR1) active compounds and pharmaceutical compositions comprising said compounds. Furthermore, the invention concerns the use of said compounds for the treatmen...
|
|
WO/2005/085180A1 |
A novel method of an amidocarbonylation reaction among an aldehyde compound, an amide compound, and carbon monoxide, which comprises using a palladium-supporting crosslinked-polymer composition containing palladium clusters having a majo...
|
|
WO/2005/082862A2 |
The present invention relates to benzimidazolyl derivatives of formula (I), with the definitions of R8, p, Ar1, E, D, R9, q and R10 according to claim 1, the use of the compounds of formula (I) as inhibitors of one or more kinases, the u...
|
|
WO/2005/075410A1 |
Compounds of formula (I), for clinical treatment of autoimmune diseases, inflammatory diseases, organ transplant rejection and malignant neoplasia. A pharmaceutical composition comprising a compound of formula (I) in an amount giving a d...
|
|
WO/2005/070871A2 |
The application relates to novel amino alcohols of general formula (I) where R, R1, R2, R3, R4, R5, X1 and X2 each have the definitions illustrated in detail in the description, to a process for their preparation and to the use of these ...
|
|
WO2005040355A3 |
The invention provides compounds and methods for inhibition of kinases, such as those of the TAO family, more specifically KIAA1361, TAO, and JIK kinases. The invention provides compounds for modulating protein kinase enzymatic activity ...
|
|
WO/2005/068417A1 |
A triphenylmethane derivative represented by the general formula (1), an organic gallant containing the derivative, an organic gel, and an organic fiber. Although the triphenylmethane derivative is a low-molecular compound, it has the ab...
|
|
WO/2005/068420A1 |
The present invention relates to novel urea and thiourea compounds, compositions comprising urea or thiourea compounds, and methods useful for treating and preventing aging, Alzheimer’s Disease, cancer, cardiovascular disease, diabetic...
|
|
WO2004050609A8 |
The invention provides compounds of formula I: useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and...
|
|
WO/2005/063699A1 |
The present invention provides N-aryloxypropanolyl-N’-phenethyl-urea derivatives of formula (3), method for their preparation and use thereof as potent appetite suppressants for treatment of obesity. Formula (3): wherein R is selected ...
|
|
WO/2005/063222A1 |
An Hsp90 family protein inhibitor which contains as an active ingredient a benzene derivative represented by the following general formula (I), a prodrug thereof, or a pharmacologically acceptable salt of either.
|
|
WO/2005/063018A1 |
Present invention relates to a haloalkene compound of the formula (I)or its salt: wherein each of X1 and X2 is halogen; Y is alkyl, haloalkyl or phenyl; n is 0 to 5; L is -C(=B)Q, -C(=B)B’Q, -C(=B)N(D)Q, -N(D)Q, -N(D)C(=B)Q, -N(D)C(=B)...
|
|
WO/2005/061445A1 |
Methods and reagents for rhodium-promoted carbonylation via isocyanate using carbon-isotope labeled carbon monoxide are provided. The resultant carbon isotope labeled compounds are useful as radiopharmaceuticals, especially for use in ...
|
|
WO/2005/061443A2 |
The invention relates to benzoyl-substituted phenylalanine amides of formula (I), wherein the variables R1 to R15 have the meanings indicated in the description, the agriculturally useful salts thereof, methods and intermediate products ...
|
|
WO2005020899A3 |
The present application describes modulators of MCP-1 of formula (I) or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.
|
|
WO/2005/058798A2 |
Compounds of formulas 1 through 17 provided in the specification specifically or selectively inhibit either the cytochrome P450RAI-1 enzyme or the cytochrome P450RAI-2 enzyme.
|
|
WO2005033230A3 |
Low-cure powder coating compositions are disclosed, comprising at least one epoxy-containing resin and/or at least one siloxane-containing resin, and at least one material having the structure formula (I) wherein R1 is an organic radic...
|
|
WO/2005/056519A1 |
The present invention provides a compound represented by the formula (I): (INSERT CHEMICAL FORMULA) (wherein R1 is a lower alkyl substituted by a lower alkoxy or a heterocyclic group, or a heterocyclic group; R2 is a lower alkyl optional...
|
